# Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia

> **NCT00112554** · PHASE3 · COMPLETED · sponsor: **Vion Pharmaceuticals** · enrollment: 420 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** cytarabine
- **DRUG:** laromustine
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00112554
- **Lead sponsor:** Vion Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2013-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00112554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00112554, "Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00112554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*